Bharat Parenterals Ltd reports Q2 FY27 revenue of ₹136.3 crore, up 110.9% YoY, with operating EBITDA margin at 17.3%
- Consolidated PAT was ₹11.8 crore, versus losses of ₹8.6 crore in Q2 FY26 and ₹3.6 crore in Q1 FY27.
- Revenue increased 45.4% QoQ; EBITDA margin compares with 1.3% in Q2 FY26 and 9.1% in Q1 FY27.
- Innoxel returned to profitability and launched its first US commercial CMO product.
- Q2 and H1 FY27 results are unaudited.